About Genmab

Company Description

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

We are the creators of three marketed products* and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.

Year founded

1999

Headquarters

Kalvebod Brygge 43, 1560 Copenhagen – Denmark

Shareholder information

Shares outstanding

65,829,282

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Copenhagen

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.